Morphine or Ketamine for Analgesia
NCT06835504
Summary
Pain is common in children presenting to the emergency department but is frequently undertreated, leading to both short- and long-term consequences. Morphine is the standard treatment for children with moderate to severe acute pain, but its use is associated with serious side effects and caregiver and clinician concerns related to opioid administration. The investigators aim to determine if sub-dissociative ketamine is non-inferior to morphine for treating acute pain and a preferable alternative for treating acute pain in children because of its more favorable side effect profile and potential long-term benefits related to pain-related function, analgesic use/misuse, and mental and behavioral health outcomes.
Eligibility
Inclusion Criteria: 1. Age 6 to \< 18 years old 2. Chief complaint includes abdominal pain OR isolated long-bone extremity fracture (suspected or proven) 3. Self-reported pain score of ≥ 6/10 4. Requires IV morphine for analgesia as determined by the treating physician Exclusion Criteria: 1. Weighs more than 81.9 kg 2. Known allergy/contraindication to morphine or ketamine 3. Antecedent receipt of ketamine related to presenting complaint 4. Inability to use self-report measures of pain or questionnaires 5. Chronic disease associated with pain 6. Chronic pain conditions requiring use of opioids as an outpatient 7. Abnormal vital signs at baseline, defined as oxygen saturation \<92% and/or low respiratory rate and/or low heart rate and/or low blood pressure per age 8. Altered mental state (e.g., GCS \< 14 or clinical intoxication) 9. Known history of schizophrenia, liver or kidney problems, or osteogenesis imperfecta 10. Concern for open fracture, neurovascular compromise, or compartment syndrome 11. Injuries in addition to the extremity injury (e.g., head, neck, abdomen) 12. Known or reported pregnancy 13. Patients who are breastfeeding 14. Patient or parent/guardian does not speak English or Spanish 15. Patient previously enrolled in this study 16. Known significant or uncontrolled cardiovascular disease 17. Known increased intracranial pressure and/or elevated intraocular pressure 18. Currently taking or having used a monoamine oxidase inhibitor within 14 days 19. Wards of state, foster children, or children in custody
Conditions6
Interventions2
Locations8 sites
Find trials near these locations
Related trials
- Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure — Dr. Inge Winter
- Ketamine Augmentation of ECT in Treatment-Resistant Depression — Università Vita-Salute San Raffaele
- Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT) — Joshua Rosenblat
- Ketamine for Combined Depression and Alcohol Use Disorder — University Hospital of North Norway
- The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. — Dr. Inge Winter
- Understanding and Treating Suicidal Ideation With Ketamine — The Royal's Institute of Mental Health Research
- Imaging Depression in Parkinson's Disease — Yale University
- Neurobiology of Suicide — National Institute of Mental Health (NIMH)
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06835504